-
AbbVie Submits NDA for Elagolix
americanpharmaceuticacreview
September 07, 2017
AbbVie in cooperation with Neurocrine Biosciences has submitted a New Drug Application (NDA) to the U.S.
-
With FDA’s Approval of the Second Biosimilar, Humira to Fight for the Glory of King!
en-cphi.cn
September 01, 2017
There comes the second FDA-approved biosimilar of AbbVie’s branded drug Humira (adalimumab), as the tumor necrosis factor (TNF) blocker Cyltezo of Boehringer Ingelheim was approved for marketing by FDA on August 25.
-
More Canadians have access to HUMIRA for the treatment of Ulcerative Colitis
firstwordpharma
August 30, 2017
HUMIRA? (adalimumab) now reimbursed in British Columbia, Ontario, New Brunswick, Newfoundland and Labrador, Saskatchewan and Yukon, it's also covered by the federal Non-Insured Health Benefits (NIHB) program.
-
With IBD market set for major growth, AbbVie stands to benefit: analyst
fiercepharma
August 24, 2017
AbbVie's pipeline contains multiple prospects to treat inflammatory bowel disease.
-
AbbVie’s pan-genotypic hep C therapy cleared in the US
pharmatimes
August 07, 2017
AbbVie’s hepatitis C therapy Mavyret has picked up an approval in the US just days after having been green lighted by regulators in Europe.
-
AbbVie receives EC grant to market HCV treatment Maviret
pharmaceutical-technology
August 02, 2017
The European Commission (EC) has granted marketing authorisation for AbbVie’s Maviret (glecaprevir / pibrentasvir) to treat adult patients with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6).
-
AbbVie loses $15 million Depakote birth-defect case
pharmafile
June 13, 2017
AbbVie loses $15 million Depakote birth-defect case
-
AbbVie loses $15 million Depakote birth-defect case
pharmafile
June 12, 2017
AbbVie loses $15 million Depakote birth-defect case
-
AbbVie, Novo, Takeda take home honors in pharma's latest reputation study
fiercepharma
June 07, 2017
Which pharma company has the best reputation? Boston-based Reputation Institute has a few ideas.
-
UK patients get early access to AbbVie’s hepatitis regimen
pharmafiles
May 12, 2017
AbbVie’s glecaprevir/pibrentasvir (G/P) has become the first treatment for chronic hepatitis C to be included in the UK’s Early Access to Medicines Scheme (EAMS).
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
